Antigenics says melanoma drug shows promise

10/11/2005 | Wall Street Journal, The

The company said preliminary results from a late-stage trial suggest its Oncophage vaccine extended the survival of advanced cancer patients by about eight months over standard therapies. The personalized cancer treatment uses malignant tumor tissue to prompt a patient's immune system to attack the cancer. Once data from the Phase III trial are analyzed, Antigenics plans to conduct a final trial before applying for FDA approval.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC